• 214/D Bir Uttam Mir Shawkat Avenue, Tejgaon- Gulshan Link Road, Dhaka
  • +880-2-8816767

Latest News

Renata Synthesized Sorafenib API first

Reanata Limited have successfully synthesized the active pharmaceutical ingredient (API), Sorafenib which is used to treat various cancers. Sorafenib is the first API of Renata Limited. Kudos to the team, may this be the first of many such projects.

Sorafenib is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), and radioactive iodine resistant advanced thyroid carcinoma.

Renata Limited (formerly Pfizer Limited) is one of the leading and fastest growing pharmaceutical and animal health product companies in Bangladesh. The company started its operations in 1972 as Pfizer (Bangladesh) Limited. In 1993, Pfizer transferred the ownership of its Bangladesh operations to local shareholders and the name of the company was changed to Renata Limited.

The core businesses of Renata Limited are human pharmaceuticals and animal health products. In Bangladesh it is the 4th largest pharmaceutical company and the market leader in animal health products. In addition, Renata products are exported to Afghanistan, Belize, Cambodia, Ethiopia, Guyana, Honduras, Hong Kong, Kenya, Malaysia, Myanmar, Nepal, Philippines, Sri Lanka, Thailand, United Kingdom and Vietnam. The company is listed on the Dhaka Stock Exchange with market capitalization of approximately Taka 50 Billion.

The company has eight manufacturing facilities spread over three manufacturing sites. In addition Renata Oncology Limited has two manufacturing facilities. Distribution of products is carried out by 19 depots across the country.